Physician profile
Thomas Head
NPI 1447355193
$1,875.26
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $294 · 2021: $794 · 2022: $416.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.33 | 2020-2022 | |
| Celgene Corporation | $212.04 | 2021-2022 | |
| Allergan, INC. | $196.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $144.95 | 2019-2022 | |
| Emd Serono, INC. | $142.08 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $136.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $94.84 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.56 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $69.57 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $55.24 | 2021 | |
| Csl Behring | $44.11 | 2019 | |
| Amgen INC. | $42.05 | 2019-2022 | |
| Genzyme Corporation | $41.71 | 2019-2020 | |
| Lilly USA, LLC | $39.66 | 2019-2020 | |
| Acorda Therapeutics, INC | $33.15 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.02 | 2020 | |
| Biogen, INC. | $28.96 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $23.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.63 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.81 | 2020 | |
| Banner Life Sciences, LLC | $15.31 | 2022 | |
| Acadia Pharmaceuticals INC | $14.65 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.31 | 2020 | |
| Vanda Pharmaceuticals INC. | $13.26 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.35 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.